sorafenib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Raf (Rapidely Accelerated Fibrosarcoma) kinase inhibitors 2459 284461-73-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • BAY 43-9006
  • BAY 545-9085
  • BAY-545-9085
  • sorafenib tosilate
  • sorafenib
  • nexavar
  • sorafenib tosylate
Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, RET/PTC, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-beta). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor angiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosis were observed in models of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma.
  • Molecular weight: 464.83
  • Formula: C21H16ClF3N4O3
  • CLOGP: 5.46
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 3
  • TPSA: 92.35
  • ALOGS: -5.43
  • ROTB: 6

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 12.29 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 39 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 20, 2005 FDA BAYER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 1482.97 19.71 449 13833 20002 46651778
Hepatocellular carcinoma 1005.73 19.71 221 14061 2618 46669162
Hepatic cancer 267.19 19.71 78 14204 3019 46668761
Blister 188.50 19.71 135 14147 44496 46627284
Hepatic function abnormal 187.84 19.71 122 14160 34299 46637481
Diarrhoea 181.12 19.71 472 13810 559130 46112650
Hepatic encephalopathy 167.07 19.71 75 14207 10082 46661698
Rash 166.87 19.71 348 13934 356164 46315616
Renal cell carcinoma 150.52 19.71 52 14230 3486 46668294
Decreased appetite 148.99 19.71 235 14047 193601 46478179
Off label use 138.68 19.71 336 13946 379505 46292275
Hypertension 123.95 19.71 218 14064 196138 46475642
Alopecia 112.54 19.71 188 14094 162226 46509554
Hyperkeratosis 108.55 19.71 45 14237 4980 46666800
Metastases to lung 106.41 19.71 56 14226 10640 46661140
Thyroid cancer 101.96 19.71 40 14242 3838 46667942
Skin exfoliation 98.08 19.71 81 14201 32857 46638923
Stomatitis 88.93 19.71 107 14175 68190 46603590
Ascites 84.79 19.71 78 14204 36506 46635274
Drug ineffective 82.90 19.71 53 14229 677785 45993995
Amylase increased 82.46 19.71 38 14244 5421 46666359
Dry skin 77.22 19.71 78 14204 40938 46630842
Product use in unapproved indication 75.51 19.71 114 14168 90159 46581621
Pain of skin 72.67 19.71 39 14243 7703 46664077
Alpha 1 foetoprotein increased 64.98 19.71 14 14268 149 46671631
Lipase increased 63.47 19.71 37 14245 8566 46663214
Rheumatoid arthritis 61.07 19.71 3 14279 240212 46431568
Metastatic renal cell carcinoma 56.33 19.71 18 14264 945 46670835
Drug hypersensitivity 53.63 19.71 6 14276 243819 46427961
Hepatic failure 52.98 19.71 58 14224 33358 46638422
Erythema multiforme 51.90 19.71 34 14248 9670 46662110
Erythema 47.19 19.71 122 14160 142698 46529082
Palmoplantar keratoderma 46.54 19.71 10 14272 105 46671675
Ammonia increased 40.94 19.71 22 14260 4355 46667425
Platelet count decreased 37.82 19.71 90 14192 99934 46571846
Hypophosphataemia 37.43 19.71 25 14257 7342 46664438
Blood bilirubin increased 37.19 19.71 49 14233 34135 46637645
Skin toxicity 35.96 19.71 19 14263 3635 46668145
Catabolic state 34.07 19.71 7 14275 58 46671722
Blood pressure increased 33.69 19.71 100 14182 126566 46545214
Liver carcinoma ruptured 33.11 19.71 5 14277 3 46671777
Pain in extremity 32.01 19.71 160 14122 258520 46413260
Weight decreased 29.39 19.71 135 14147 210714 46461066
Hyperammonaemia 28.88 19.71 18 14264 4698 46667082
Pancreatic enzymes increased 28.73 19.71 10 14272 685 46671095
Condition aggravated 28.65 19.71 20 14262 245032 46426748
Protein induced by vitamin K absence or antagonist II increased 28.37 19.71 4 14278 0 46671780
Thyroid cancer metastatic 28.33 19.71 7 14275 141 46671639
Liver disorder 28.24 19.71 45 14237 37201 46634579
Food refusal 28.08 19.71 8 14274 283 46671497
Tumour necrosis 27.66 19.71 10 14272 765 46671015
Sinusitis 26.56 19.71 4 14278 129764 46542016
Oral pain 26.13 19.71 35 14247 24762 46647018
Weight increased 25.89 19.71 9 14273 164464 46507316
Hospitalisation 24.99 19.71 58 14224 63327 46608453
Abdominal pain 24.80 19.71 137 14145 229894 46441886
Plantar erythema 24.32 19.71 7 14275 257 46671523
Pyrexia 23.73 19.71 185 14097 348617 46323163
Acute myeloid leukaemia 22.63 19.71 26 14256 15752 46656028
Tumour thrombosis 22.36 19.71 4 14278 14 46671766
Bronchitis 22.31 19.71 3 14279 105976 46565804
Gait inability 21.99 19.71 39 14243 35164 46636616
Soft tissue necrosis 21.45 19.71 7 14275 393 46671387
Pneumonia 20.38 19.71 54 14228 376266 46295514
Mucosal inflammation 20.37 19.71 40 14242 38936 46632844
Fatigue 20.33 19.71 279 14003 608418 46063362
Hepatic rupture 20.32 19.71 4 14278 26 46671754
Malignant neoplasm progression 19.91 19.71 54 14228 64872 46606908
Hypocalcaemia 19.81 19.71 32 14250 26753 46645027

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatocellular carcinoma 3769.33 15.59 1058 34238 8552 29908630
Palmar-plantar erythrodysaesthesia syndrome 3630.16 15.59 1134 34162 13736 29903446
Hepatic cancer 1052.18 15.59 365 34931 6183 29910999
Hepatic function abnormal 622.44 15.59 462 34834 41483 29875699
Hepatic encephalopathy 546.60 15.59 287 35009 13905 29903277
Diarrhoea 541.60 15.59 1201 34095 332902 29584280
Ascites 489.14 15.59 376 34920 35545 29881637
Renal cell carcinoma 430.22 15.59 184 35112 5582 29911600
Decreased appetite 410.06 15.59 675 34621 149235 29767947
Hypertension 373.59 15.59 577 34719 120777 29796405
Alopecia 318.86 15.59 227 35069 19048 29898134
Metastases to lung 310.50 15.59 162 35134 7733 29909449
Hepatic failure 306.93 15.59 281 35015 33762 29883420
Blister 252.13 15.59 203 35093 20480 29896702
Dysphonia 245.26 15.59 193 35103 18839 29898343
Alpha 1 foetoprotein increased 209.71 15.59 63 35233 652 29916530
Rash 182.02 15.59 567 34729 191322 29725860
Amylase increased 158.73 15.59 94 35202 5747 29911435
Liver carcinoma ruptured 142.50 15.59 33 35263 105 29917077
Metastatic renal cell carcinoma 130.08 15.59 62 35234 2430 29914752
Ammonia increased 127.81 15.59 73 35223 4168 29913014
Drug ineffective 124.56 15.59 131 35165 340256 29576926
Toxicity to various agents 115.35 15.59 33 35263 177150 29740032
Blood bilirubin increased 114.75 15.59 176 35120 36460 29880722
Hyperkeratosis 109.88 15.59 61 35235 3296 29913886
Stomatitis 109.68 15.59 174 35122 37105 29880077
Skin exfoliation 106.63 15.59 134 35162 23038 29894144
Drug interaction 103.67 15.59 53 35243 199515 29717667
Completed suicide 99.91 15.59 4 35292 99488 29817694
Lipase increased 99.02 15.59 82 35214 8594 29908588
Liver disorder 97.62 15.59 146 35150 29576 29887606
Jaundice 97.45 15.59 153 35143 32333 29884849
Acute kidney injury 91.75 15.59 113 35183 273729 29643453
Oesophageal varices haemorrhage 90.55 15.59 52 35244 2999 29914183
Metastases to bone 89.41 15.59 81 35215 9577 29907605
Dry skin 83.50 15.59 117 35179 22337 29894845
Fatigue 79.86 15.59 647 34649 320026 29597156
Overdose 79.56 15.59 5 35291 84332 29832850
Hypophosphataemia 78.00 15.59 70 35226 8175 29909007
Tumour rupture 76.78 15.59 21 35275 150 29917032
Metastases to lymph nodes 73.08 15.59 50 35246 3927 29913255
Abdominal pain 66.57 15.59 326 34970 135328 29781854
Pain of skin 66.40 15.59 46 35250 3687 29913495
Platelet count decreased 66.28 15.59 274 35022 105855 29811327
Blood pressure increased 65.51 15.59 210 35086 71718 29845464
Portal vein thrombosis 64.72 15.59 44 35252 3420 29913762
Tumour thrombosis 59.43 15.59 14 35282 49 29917133
Abdominal pain upper 57.29 15.59 183 35113 62368 29854814
Fall 55.74 15.59 80 35216 181792 29735390
Pneumonia 54.89 15.59 206 35090 334100 29583082
Hepatorenal syndrome 54.44 15.59 35 35261 2476 29914706
Erythema multiforme 53.32 15.59 56 35240 7929 29909253
Pain in extremity 52.69 15.59 263 35033 109958 29807224
Hypotension 52.35 15.59 98 35198 200467 29716715
Aspartate aminotransferase increased 52.23 15.59 179 35117 63243 29853939
Weight decreased 50.94 15.59 328 34968 150593 29766589
Off label use 50.44 15.59 481 34815 248809 29668373
Protein induced by vitamin K absence or antagonist II increased 49.58 15.59 10 35286 12 29917170
Neutropenia 48.46 15.59 48 35248 128492 29788690
Drug hypersensitivity 47.89 15.59 11 35285 68508 29848674
Pancreatic enzymes increased 47.34 15.59 20 35276 587 29916595
Coma hepatic 45.67 15.59 18 35278 440 29916742
Metastases to spine 45.35 15.59 30 35266 2228 29914954
Skin fissures 44.53 15.59 35 35261 3404 29913778
Asthenia 44.24 15.59 426 34870 220864 29696318
Metastases to central nervous system 43.23 15.59 48 35248 7236 29909946
Metastases to adrenals 42.37 15.59 21 35275 897 29916285
Cardiac arrest 40.69 15.59 30 35266 92820 29824362
Skin toxicity 39.78 15.59 32 35264 3217 29913965
Hepatic rupture 39.77 15.59 9 35287 25 29917157
Liver abscess 39.67 15.59 32 35264 3230 29913952
Renal cell carcinoma stage IV 39.59 15.59 10 35286 50 29917132
Metastases to peritoneum 39.55 15.59 24 35272 1533 29915649
Coronary artery disease 38.95 15.59 6 35290 49706 29867476
Gait inability 37.33 15.59 74 35222 18767 29898415
Malignant neoplasm progression 37.02 15.59 176 35120 72111 29845071
Tumour marker increased 36.84 15.59 16 35280 503 29916679
Condition aggravated 36.25 15.59 67 35229 137799 29779383
Depression 36.15 15.59 32 35264 90405 29826777
Weight increased 35.77 15.59 22 35274 74891 29842291
Anxiety 34.50 15.59 33 35263 89838 29827344
Reactive perforating collagenosis 34.47 15.59 6 35290 0 29917182
Febrile neutropenia 33.57 15.59 46 35250 106647 29810535
Thyroid cancer metastatic 32.93 15.59 8 35288 33 29917149
Cerebral infarction 32.66 15.59 86 35210 26287 29890895
Aggression 32.49 15.59 3 35293 36904 29880278
Foetal exposure during pregnancy 32.45 15.59 3 35293 36868 29880314
Agitation 31.72 15.59 12 35284 54061 29863121
Tumour haemorrhage 31.17 15.59 25 35271 2503 29914679
Varicose vein ruptured 30.79 15.59 7 35289 20 29917162
Product administered to patient of inappropriate age 28.94 15.59 24 35272 2519 29914663
Bradycardia 28.92 15.59 21 35275 65505 29851677
Nephrotic syndrome 28.80 15.59 38 35258 6847 29910335
Gastric ulcer 28.29 15.59 58 35238 15063 29902119
Hospitalisation 28.06 15.59 115 35181 44204 29872978
Hepatic cancer metastatic 27.43 15.59 14 35282 637 29916545
Haemobilia 27.28 15.59 11 35285 286 29916896
Cancer pain 27.20 15.59 23 35273 2479 29914703
Suicidal ideation 26.87 15.59 5 35291 36109 29881073
Influenza 26.53 15.59 9 35287 43389 29873793
General physical health deterioration 26.50 15.59 205 35091 99739 29817443
Lactic acidosis 26.28 15.59 3 35293 31210 29885972
Hyperamylasaemia 25.87 15.59 13 35283 572 29916610
Chronic obstructive pulmonary disease 25.81 15.59 11 35285 46115 29871067
Hyperammonaemia 25.50 15.59 32 35264 5488 29911694
Thyroid cancer 25.39 15.59 17 35279 1288 29915894
Intentional product misuse 25.37 15.59 5 35291 34662 29882520
Plantar erythema 25.24 15.59 7 35289 53 29917129
Cardiac failure congestive 24.95 15.59 38 35258 84369 29832813
Oxygen saturation decreased 24.88 15.59 10 35286 43430 29873752
Rhabdomyolysis 24.80 15.59 23 35273 63557 29853625
Papillary thyroid cancer 24.77 15.59 13 35283 627 29916555
Erythema 24.65 15.59 166 35130 77285 29839897
C-reactive protein increased 24.58 15.59 109 35187 43364 29873818
Therapeutic product effect incomplete 24.51 15.59 5 35291 33829 29883353
Cardio-respiratory arrest 24.47 15.59 19 35277 57287 29859895
Genital rash 24.33 15.59 12 35284 507 29916675
Malaise 24.31 15.59 302 34994 166660 29750522
Keratoacanthoma 24.25 15.59 12 35284 511 29916671
Tachycardia 23.99 15.59 31 35265 73708 29843474
Therapeutic product effect decreased 23.97 15.59 3 35293 29073 29888109
Abdominal distension 23.90 15.59 112 35184 45597 29871585
Metastasis 23.59 15.59 24 35272 3274 29913908
Syncope 23.43 15.59 40 35256 84863 29832319
Nasopharyngitis 23.29 15.59 21 35275 58828 29858354
Glossodynia 23.21 15.59 24 35272 3337 29913845
Gastric antral vascular ectasia 23.07 15.59 10 35286 313 29916869
Inappropriate schedule of product administration 23.00 15.59 9 35287 39719 29877463
Hepatic cancer stage IV 22.98 15.59 4 35292 0 29917182
Hypersensitivity 22.96 15.59 18 35278 54010 29863172
Epistaxis 22.89 15.59 123 35173 52858 29864324
Chronic kidney disease 22.86 15.59 8 35288 37830 29879352
Electrocardiogram QT prolonged 22.67 15.59 7 35289 35828 29881354
Pyrexia 22.66 15.59 479 34817 294010 29623172
Incorrect dose administered 22.30 15.59 5 35291 31681 29885501
Sinusitis 22.03 15.59 6 35290 33339 29883843
Hepatic infarction 21.43 15.59 8 35288 168 29917014
Asthma 21.26 15.59 8 35288 36166 29881016
Drug reaction with eosinophilia and systemic symptoms 21.07 15.59 4 35292 28484 29888698
Hyperhidrosis 21.01 15.59 29 35267 67061 29850121
Psoriasis 20.96 15.59 12 35284 42494 29874688
Hepatic lesion 20.95 15.59 22 35274 3114 29914068
Skin ulcer 20.87 15.59 59 35237 18790 29898392
Palmoplantar keratoderma 20.69 15.59 9 35287 284 29916898
Varices oesophageal 20.61 15.59 23 35273 3486 29913696
Gingival bleeding 20.35 15.59 31 35265 6373 29910809
Haematemesis 19.86 15.59 72 35224 26131 29891051
Neuropathy peripheral 19.63 15.59 33 35263 70442 29846740
Alanine aminotransferase increased 19.48 15.59 152 35144 74124 29843058
Lower respiratory tract infection 19.24 15.59 4 35292 26710 29890472
Death 19.06 15.59 553 34743 356730 29560452
Dizziness 19.03 15.59 143 35153 194766 29722416
Metastases to pleura 18.73 15.59 9 35287 359 29916823
Sepsis 18.61 15.59 99 35197 146296 29770886
Hepatic artery thrombosis 18.35 15.59 8 35288 254 29916928
Proteinuria 18.33 15.59 51 35245 16094 29901088
Wrong technique in product usage process 18.13 15.59 7 35289 31148 29886034
Melaena 18.08 15.59 81 35215 32356 29884826
Wheezing 17.92 15.59 7 35289 30931 29886251
Aortic dissection 17.88 15.59 18 35278 2424 29914758
Renal cancer metastatic 17.83 15.59 10 35286 551 29916631
Glossitis 17.74 15.59 13 35283 1138 29916044
Urticaria 17.71 15.59 23 35273 54583 29862599
Hallucination 17.69 15.59 19 35277 49040 29868142
Septic shock 17.51 15.59 30 35266 63577 29853605
Product dose omission issue 17.30 15.59 53 35243 91578 29825604
Metastases to gallbladder 17.23 15.59 3 35293 0 29917182
Thyroid atrophy 17.23 15.59 3 35293 0 29917182
Poorly differentiated thyroid carcinoma 17.23 15.59 3 35293 0 29917182
Joint swelling 17.13 15.59 18 35278 46928 29870254
Oropharyngeal blistering 16.98 15.59 7 35289 193 29916989
Intentional product use issue 16.97 15.59 11 35285 36429 29880753
Leukopenia 16.87 15.59 25 35271 56134 29861048
Dyspnoea 16.85 15.59 284 35012 333011 29584171
Therapeutic response decreased 16.82 15.59 4 35292 24345 29892837
Faeces discoloured 16.78 15.59 45 35251 13901 29903281
Hypoalbuminaemia 16.71 15.59 39 35257 11053 29906129
Feeding disorder 16.69 15.59 27 35269 5844 29911338
Tumour embolism 16.53 15.59 5 35291 53 29917129
Somnolence 16.19 15.59 59 35237 96704 29820478
Cytomegalovirus infection 16.14 15.59 4 35292 23670 29893512
Scrotal ulcer 16.11 15.59 8 35288 343 29916839
Skin reaction 15.96 15.59 23 35273 4502 29912680
Urinary tract infection 15.84 15.59 40 35256 73619 29843563

Pharmacologic Action:

SourceCodeDescription
ATC L01EX02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Other protein kinase inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors
CHEBI has role CHEBI:48422 angiostatic agents
CHEBI has role CHEBI:50925 serine/threonine protein kinase inhibitors
CHEBI has role CHEBI:149553 anti-coronaviral agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Liver cell carcinoma indication 109841003 DOID:684
Carcinoma of thyroid indication 448216007
Renal cell carcinoma indication 702391001 DOID:4450
Hypophosphatemia contraindication 4996001
Acute hemorrhage contraindication 8573003
Myocardial infarction contraindication 22298006 DOID:5844
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal perforation contraindication 51875005
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Pancreatitis contraindication 75694006 DOID:4989
Angina pectoris contraindication 194828000
Impaired wound healing contraindication 271618001
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Surgical procedure contraindication 387713003
Acute coronary syndrome contraindication 394659003
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.84 acidic
pKa2 11.97 acidic
pKa3 12.61 acidic
pKa4 2.76 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase INHIBITOR Kd 8.13 CHEMBL CHEMBL
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 7.80 CHEMBL CHEMBL
Serine/threonine-protein kinase B-raf Kinase INHIBITOR Ki 7.66 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR Kd 7.80 CHEMBL CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase INHIBITOR Ki 8.22 CHEMBL CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase INHIBITOR Kd 8.35 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR Kd 7.51 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR Ki 10.68 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 7.43 CHEMBL CHEMBL
Myosin-IIIb Kinase Kd 5.15 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.93 CHEMBL
Cyclin-dependent kinase 15 Kinase Kd 5.54 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 5.89 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 5.74 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 5.12 CHEMBL
Aurora kinase A Kinase IC50 5.42 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 6.72 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 8.20 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 6.41 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 5.77 CHEMBL
Cyclin-dependent kinase-like 3 Kinase Kd 6.31 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 6.38 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 5.71 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 5.51 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 5.32 CHEMBL
Mitogen-activated protein kinase 15 Kinase Kd 7.34 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1 Kinase Kd 6.64 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 5.11 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 6.16 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 6.36 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 5.12 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 5.96 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 6.02 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 5.46 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 5.70 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.72 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 5.47 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.14 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 5.54 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 6.27 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 6.55 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 5.07 CHEMBL
Aurora kinase C Kinase Kd 6.68 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 5.44 CHEMBL
Fibroblast growth factor receptor 1 Kinase Kd 5.60 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 5.57 CHEMBL
Citron Rho-interacting kinase Kinase Kd 5.21 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 8.57 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 5.80 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 5.42 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 6.62 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 5.10 CHEMBL
Aurora kinase B Kinase Kd 6.36 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 6 CHEMBL
5-hydroxytryptamine receptor 2B GPCR Ki 7.25 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2 Kinase Kd 6.89 CHEMBL
Ephrin type-A receptor 7 Kinase Kd 6.17 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 6.27 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 5.52 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 6.44 CHEMBL
LIM domain kinase 1 Kinase Kd 5.80 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 5.89 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 5.77 CHEMBL
NT-3 growth factor receptor Kinase Kd 6.22 CHEMBL
Cyclin-dependent kinase 2 Kinase Kd 5.06 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 5.89 CHEMBL
Angiopoietin-1 receptor Kinase Kd 5.68 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.62 CHEMBL
5-hydroxytryptamine receptor 5A GPCR Ki 5.48 CHEMBL
Bifunctional epoxide hydrolase 2 Enzyme IC50 7.92 CHEMBL
5-hydroxytryptamine receptor 6 GPCR Ki 5.21 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 5.57 CHEMBL
Tyrosine-protein kinase Srms Kinase Kd 5.01 CHEMBL
Casein kinase I isoform alpha Kinase IC50 6.60 CHEMBL
Cyclin-dependent kinase 3 Kinase Kd 5.42 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 6.85 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.08 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.55 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 8.18 CHEMBL
Cyclin-dependent kinase 17 Kinase Kd 5.80 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 7.17 CHEMBL
Cyclin-dependent kinase 14 Kinase Kd 5.54 CHEMBL
TGF-beta receptor type-2 Kinase Kd 5.16 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 8.82 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 5.32 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 5.57 CHEMBL
Mitogen-activated protein kinase 13 Kinase Kd 5.18 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.89 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 5.35 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 5.68 CHEMBL
Ephrin type-B receptor 2 Kinase Kd 5.72 CHEMBL
Mitogen-activated protein kinase 11 Kinase Kd 6.70 CHEMBL
LIM domain kinase 2 Kinase Kd 5.02 CHEMBL
Myosin light chain kinase 3 Kinase Kd 5.02 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 5.15 CHEMBL
Cyclin-dependent-like kinase 5 Kinase Kd 5.21 CHEMBL
Cyclin-dependent kinase 19 Kinase Kd 6.60 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 5.62 CHEMBL
Serine/threonine-protein kinase NLK Kinase Kd 6.19 CHEMBL
Mitogen-activated protein kinase 12 Kinase Kd 5.12 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 5.44 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 6.59 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 5.64 CHEMBL
Mitogen-activated protein kinase 3 Kinase IC50 7.74 CHEMBL
Mitogen-activated protein kinase 1 Kinase IC50 6.96 CHEMBL
Cyclin-dependent kinase 8 Kinase Kd 6.51 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 6.89 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 6.89 CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase Kinase Kd 6.89 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.44 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase IC50 6.41 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 5.38 CHEMBL
Insulin receptor Kinase AGONIST IC50 5.28 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 7.21 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 5.59 CHEMBL
Tyrosine-protein kinase ABL1 Kinase IC50 6.65 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 6.66 CHEMBL
Purine nucleoside phosphorylase Unclassified IC50 7.90 CHEMBL
Platelet-derived growth factor receptor beta Unclassified INHIBITOR IC50 7.24 IUPHAR
Vascular endothelial growth factor receptor 3 Unclassified INHIBITOR IC50 7.70 IUPHAR

External reference:

IDSource
4025077 VUID
N0000175349 NUI
D06272 KEGG_DRUG
475207-59-1 SECONDARY_CAS_RN
4025077 VANDF
C1174389 UMLSCUI
CHEBI:50928 CHEBI
BAX PDB_CHEM_ID
CHEMBL1336 ChEMBL_ID
CHEMBL1200485 ChEMBL_ID
D000077157 MESH_DESCRIPTOR_UI
216239 PUBCHEM_CID
5711 IUPHAR_LIGAND_ID
8234 INN_ID
DB00398 DRUGBANK_ID
9ZOQ3TZI87 UNII
495881 RXNORM
20792 MMSL
73580 MMSL
d05691 MMSL
011160 NDDF
011161 NDDF
420681006 SNOMEDCT_US
422042001 SNOMEDCT_US
432886002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nexavar HUMAN PRESCRIPTION DRUG LABEL 1 50419-488 TABLET, FILM COATED 200 mg ORAL NDA 29 sections